Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Chandler Thibodaux

Physician Assistant Fort Worth, TX Physician Assistant

NPI 1205974045 CMS profile 10560552

1307 8Th Ave Ste 505, Fort Worth, TX 76104

Open in the dashboard

General payments

$14,173

638 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Chandler Thibodaux of Fort Worth, TX is reported in the CMS Open Payments database as having received $14,173 across 638 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,934 130
2024 General $2,665 113
2023 General $2,847 126
2022 General $3,156 142
2021 General $2,571 127

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chandler Thibodaux
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Chandler Thibodaux were reported at $2,934. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Chandler Thibodaux Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,571 $132 $37–$438 $132
2022 $3,156 $155 $48–$522 $149
2023 $2,847 $167 $52–$557 $160
2024 $2,665 $178 $55–$600 $164
2025 $2,934 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Genzyme Corporation $2,342 65 payments
  2. AbbVie, Inc. $2,066 93 payments
  3. Novartis Pharmaceuticals Corporation $1,379 65 payments
  4. Sun Pharmaceutical Industries Inc. $1,337 62 payments
  5. Regeneron Healthcare Solutions, Inc. $1,189 49 payments
  6. Amgen Inc. $966 41 payments
  7. UCB, Inc. $829 51 payments
  8. Janssen Biotech, Inc. $737 34 payments
  9. Arcutis Biotherapeutics, Inc. $572 33 payments
  10. Galderma Laboratories, L.P. $415 20 payments
  11. Other $2,341 125 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,050 636 payments
  2. Education $123 2 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $3,283 89 payments
  2. RINVOQ $1,269 52 payments
  3. Otezla $966 41 payments
  4. COSENTYX Immunology $742 36 payments
  5. DUPIXENT Inflammation And Immunology $664 30 payments
  6. SKYRIZI $589 29 payments
  7. ILUMYA $580 22 payments
  8. COSENTYX Dermatology $567 26 payments
  9. TREMFYA $471 20 payments
  10. Bimzelx $462 30 payments
  11. Other $7,227 380 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

932

Median for Physician Assistant: 241

Drug cost

$483,878

Median for Physician Assistant: $4,110

Branded share of claims

14.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 16 $338,933
Taltz Autoinjector Ixekizumab Brand 11 $75,644
Dupixent Pen Dupilumab Brand 12 $46,076
Clobetasol Propionate Generic 146 $5,618
Ciclopirox Ciclopirox Olamine Brand 47 $2,502
Triamcinolone Acetonide Generic 106 $1,808
Fluorouracil Generic 23 $1,770
Doxycycline Hyclate Generic 57 $1,530
Clindamycin Phosphate Generic 30 $1,035
Ciclopirox Generic 21 $960

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$78,845

Medicare's payments for the services billed

Medicare patients

571

Average age 76

Services billed

2,018

267 women, 304 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Chronic kidney disease 27%
Diabetes 23%
Ischemic heart disease 23%
Depression 21%
Atrial fibrillation 18%
Cancer 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $634
  • Regeneron Healthcare Solutions, Inc. $222
$856 12 —
RINVOQ
  • AbbVie, Inc. $217
$217 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $210
$210 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $198
$198 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $165
$165 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

638 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record